Fed Governor Adriana Kugler to resign
EDEN PRAIRIE, Minn. - NeuroOne Medical Technologies Corporation (NASDAQ:NMTC), a $51.31 million market cap medical technology company whose shares have surged 42% in the past week, has received a notice of allowance from the U.S. Patent and Trademark Office for a patent titled "Methods for Making Probe Devices and Related Devices," the company announced Wednesday. According to InvestingPro data, the stock is currently trading at $1.03, showing strong momentum despite appearing overvalued based on Fair Value analysis.
The patent application (17/392,773) covers methods of manufacturing neural probe devices, including specific processes for component arrangement and electrode contact material deposition. NeuroOne expects the patent to be formally issued in the coming months.
This addition will expand the company’s intellectual property portfolio, which currently includes 17 issued and pending patents in the U.S. and internationally for various thin-film electrode technologies.
"One of the key aspects with this patent relates to the novel method of electrode material deposition for all of our electrodes that are both commercially available and in development," said Dave Rosa, Chief Executive Officer of NeuroOne.
The medical technology company focuses on developing minimally invasive solutions for EEG recording, monitoring, ablation, drug delivery, and stimulation for patients with neurological disorders including epilepsy, Parkinson’s disease, dystonia, and essential tremors.
The patent allowance represents a step in protecting the company’s technology platform as it continues developing new applications, according to the press release statement.
A notice of allowance is issued after the USPTO examines a patent application and determines that a patent should be granted. While the company posted impressive revenue growth of 54.53% in the last twelve months, InvestingPro analysis reveals 12 additional key insights about NMTC’s financial health and growth prospects. Get the complete picture with the comprehensive Pro Research Report, available exclusively to subscribers.
In other recent news, NeuroOne Medical Technologies Corp reported its first-quarter 2025 earnings, which showed mixed results. The company’s earnings per share (EPS) were -$0.07, surpassing analyst expectations of -$0.09. However, revenue fell short of projections, reaching $1.4 million compared to the anticipated $2.4 million. Despite the revenue miss, the earnings beat suggests some positive aspects in the company’s financial performance. These developments are important for investors to consider when evaluating the company’s recent performance. The earnings results indicate a complex financial landscape for NeuroOne Medical, with both positive and negative elements. Investors and analysts will likely be closely monitoring the company’s next moves.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.